UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

June 4, 2020

 

TAURIGA SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Florida   000-53723   30-0791746

(State or other jurisdiction

of incorporation)

 

(Commission

File #)

 

(IRS Employer

Identification Number)

 

555 Madison Avenue, 5th Floor

New York, NY

(Address of principal executive office)

 

Tel: (917) 796-9926

(Registrant’s telephone number)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.00001 per share   TAUG   OTCQB

 

 

 

     

 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information disclosed in Item 7.01 of this current report on Form 8-K are incorporated by reference in this Item 2.03.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information disclosed in Item 7.01 of this current report on Form 8-K are incorporated by reference in this Item 3.02.

 

In addition, on July 10, 2020, the Company’s chief executive officer purchased 700,000 shares of the Company’s Common Stock for an aggregate purchase price of $35,000, at $0.05 per share. All such shares shall be “restricted securities” as such term is defined by the Securities Act of 1933, as amended. The proceeds of this private placement were used to pay for additional inventory of the Company’s Pear Bellini flavor Tauri-Gum™. This acquisition of shares was also reported on Form 4 with the Securities and Exchange Commission on July 10, 2020.

 

Item 7.01 Regulation FD

 

On June 4, 2020, the Company entered into a one year 8% $33,000 convertible Note with GS Capital Partners, LLC (the “GS Note”) pursuant to the terms of a Securities Purchase Agreement (the “SPA”). The GS Note has a maturity date of June 4, 2021 and carried a $3,000 original issue discount (such that $30,000 was funded to the Company on or about June 4, 2020). The holder is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Note then outstanding into shares of the Company’s common stock at a price for each share of common stock equal to 65% of the lowest daily volume weighted average price (VWAP) of the common stock as reported on the National Quotations Bureau OTC Markets exchange, which the Company’s shares are traded or any exchange upon which the common stock may be traded in the future, for the twenty (20) prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. Such conversion shall be effectuated by the Company delivering the shares of common stock to the holder within 3 business days of receipt by the Company of the notice of conversion. Accrued but unpaid interest shall be subject to conversion. To the extent the conversion price of the Company’s common stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 55% instead of 65% while that “Chill” is in effect. In no event shall the holder be allowed to affect a conversion if such conversion, along with all other shares of the Company common stock beneficially owned by the holder and its affiliates would exceed 9.9% of the outstanding shares of the common stock of the Company.

 

During the first six months that the GS Capital Note is in effect, the Company may redeem the GS Note by paying to the holder an amount as follows: (i) if the redemption is within the first 90 days of the issuance date, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day, but less than the 180th day of the issuance date, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. The GS Note may not be redeemed after 180 days. The Company may not redeem the GS Capital Note after the 180th day from entering into it. Upon an event of default, among other default provisions set forth in the GS Capital Note, (i) interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. (ii) if the Company shall fail to deliver to the holder the shares of common stock without restrictive legend (when permissible in accordance with applicable law) within three (3) business days of its receipt of a notice of conversion, then the Company shall pay a penalty of $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company (which shall be increased to $500 per day beginning on the 10th day); (iii) if the Company loses its bid price for its stock in a market (including the OTC marketplace or other exchange), the principal amount due under the GS note shall increase by 20%; (iv) if the Company’s stock ceases to be listed on an exchange, its stock is suspended from trading for more than 10 consecutive trading days or the Company ceases to file its reports with the SEC under the Securities Exchange Act of 1934, as amended, then the outstanding principal due under the GS Capital Note shall increase by 50%; or (v) if the GS Capital Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%.

 

     

 

 

In connection with the GS Capital Note, the Company issued irrevocable transfer agent instructions reserving 3,678,000 shares of its common Stock for conversions under this Note (the “Share Reserve”) and shall maintain a 2.5 times reserve for the amount then outstanding. Upon full conversion or repayment of this Note, any shares remaining in the Share Reserve shall be cancelled and placed back into the treasury of the company and available for issuance at a future date.

 

The Company issued to the noteholder 90,000 shares of its restricted common stock as debt commitment shares valued at $3,105 ($0.0345 per share).

 

The foregoing description of the SPA and GS Note do not purport to be complete and are qualified in their entirety by reference to the respective agreements, which are filed as exhibits 4.1 and 4.2 to this Current Report on Form 8-K, and are incorporated herein by reference.

 

Item 8.01 Other Events.

 

Mr. Checkout Distribution Agreement

 

On July 6, 2020, the Company issued a press release announcing that it had entered into a “Go-To-Market” distribution agreement (the “Agreement”) on June 29, 2020 with Mr. Checkout Distributors (“Mr. Checkout”), a marketing and consulting company located in Oviedo, Florida. The Agreement enables the Company to launch its flagship brand Tauri-Gum™ through Mr. Checkout’s network of independent direct store distributors that service approximately 150,000 stores and retail locations across the United States. These stores include well-known convenience stores, gas station marts and supermarket chains.

 

Under this Agreement, on July 7, 2020, the Company paid a one-time $5,000 retainer on commission against the first $100,000 in sales. Subsequent commissions shall be paid to Mr. Checkout during the first thirty (30) days of the subsequent quarter once retainer has been met and exceeded. Commission will not be paid until the retainer has been met.

 

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, which is filed as exhibit 10.1 to this Current Report on Form 8-K, and is incorporated herein by reference.

 

The information set forth in the press release attached hereto as Exhibit 99.1 is hereby furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall the information in such press release filed an exhibit herewith be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Kushco Holdings Product Placement Agreement

 

Effective July 10, 2020, the Company and KushCo Holdings, Inc, a Nevada corporation (“KushCo”), entered into a Product Placement Membership Agreement (the “Placement Agreement”). Under the terms of the Placement Agreement, Kushco will provide placement services of the Company’s Tauri-Gum™ product line(s), and will assist with retail activation, product incubation, branding and marketing solutions, and sales management services. As compensation for providing such services and placement of the Company’s products, when Kushco or one of its affiliates consummates a purchase, distribution or sale of products (either directly or through third parties), Kushco will be paid a fee equal to 10% of the total gross sales for such transaction(s) (the “Placement Fee”). The Placement Fee shall be earned as of the date of the respective transaction and shall be paid in cash by the Company on a monthly basis and no later than the last calendar day of each calendar month. The Placement Agreement has a term of two (2) years, unless earlier terminated upon sixty (60) days notice to the Company, as provided under the Kuscho Agreement.

 

The foregoing description of the Placement Agreement does not purport to be complete and is qualified in its entirety by reference to the Placement Agreement, which is filed as exhibit 10.2 to this Current Report on Form 8-K, and is incorporated herein by reference.

 

Item 9.01 Exhibits Statements and Exhibits

 

(d) Exhibits

 

Exhibit
Number
  Description
     
4.1   Securities Purchase Agreement between the Company and GS Capital LLC dated June 4, 2020
4.2   Convertible Note between the Company and GS Capital LLC dated June 4, 2020
10.1   Mr. Checkout distributor agreement dated June 29, 2020
10.2   Product Placement Membership Agreement between the Company and KushCo Holdings, Inc., dated July 10, 2020
99.1   Press Release, date July 6, 2020

 

     

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 14, 2020

 

TAURIGA SCIENCES, INC.    
     
By: /s/ Seth M. Shaw  
  Seth M. Shaw  
  Chief Executive Officer  

 

     

 

 

Exhibit 4.1

 

SECURITIES PURCHASE AGREEMENT

 

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of June 4, 2020, by and between Tauriga Sciences, Inc., a Florida corporation, with headquarters located at 555 Madison Avenue, 5th Floor, New York, NY 10022 (the “Company”), and GS CAPITAL PARTNERS, LLC, with its address at 30 Washington Street, Suite 5L, Brooklyn, NY 11201 (the “Buyer”).

 

WHEREAS:

 

A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”);

 

B. Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement an 8% convertible note of the Company, in the form attached hereto as Exhibit A in the aggregate principal amount of $33,000.00 (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note. The Note shall contain a $3,000.00 original issue discount (OID) such that the purchase price shall be $30,000.00.

 

C. The Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of Note as is set forth immediately below its name on the signature pages hereto; and

 

NOW THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

 

1. Purchase and Sale of Note.

 

a. Purchase of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages hereto.

 

sms 

 

Company Initials

 

  1  

 

 

b. Form of Payment. On the Closing Date (as defined below), (i) the Buyer shall pay the purchase price for the Note to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and (ii) the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price.

 

c. Closing Date. The date and time of the first issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be on or about June 4, 2020, or such other mutually agreed upon time. The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

 

2. Buyer’s Representations and Warranties. The Buyer represents and warrants to the Company that:

 

a. Investment Purpose. As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise pursuant to the Note, such shares of Common Stock being collectively referred to herein as the “Conversion Shares” and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act; provided, however, that by making the representations herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.

 

b. Accredited Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

 

c. Reliance on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

 

d. Information. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company’s representations and warranties made herein.

 

  2  

 

 

e. Governmental Review. The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

 

f. Transfer or Re-sale. The Buyer understands that (i) the sale or re- sale of the Securities has not been and is not being registered under the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold pursuant to an effective registration statement under the 1933 Act, (b) the Buyer shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration, which opinion shall be accepted by the Company, (c) the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a successor rule) (“Rule 144”) of the Buyer who agrees to sell or otherwise transfer the Securities only in accordance with this Section 2(f) and who is an Accredited Investor, (d) the Securities are sold pursuant to Rule 144, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation S”), and the Buyer shall have delivered to the Company, at the cost of the Buyer, an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate transactions, which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation to register such Securities under the 1933 Act or any state securities laws or to comply with the terms and conditions of any exemption thereunder (in each case). Notwithstanding the foregoing or anything else contained herein to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending arrangement.

 

  3  

 

 

g. Legends. The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Conversion Shares may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):

 

“NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected. The Buyer agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144 or Regulation S, within 2 business days, it will be considered an Event of Default under the Note.

 

h. Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

 

i. Residency. The Buyer is a resident of the jurisdiction set forth immediately below the Buyer’s name on the signature pages hereto.

 

j. No Short Sales. Buyer/Holder, its successors and assigns, agree that so long as the Note remains outstanding, the Buyer/Holder shall not enter into or effect “short sales” of the Common Stock or hedging transaction which establishes a short position with respect to the Common Stock of the Company. The Company acknowledges and agrees that upon delivery of a Conversion Notice by the Buyer/Holder, the Buyer/Holder immediately owns the shares of Common Stock described in the Conversion Notice and any sale of those shares issuable under such Conversion Notice would not be considered short sales.

 

  4  

 

 

3. Representations and Warranties of the Company. The Company represents and warrants to the Buyer that:

 

a. Organization and Qualification. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.

 

b. Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

c. Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

 

d. Acknowledgment of Dilution. The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance of the Conversion Shares upon conversion of the Note. The Company further acknowledges that its obligation to issue Conversion Shares upon conversion of the Note in accordance with this Agreement, the Note is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

 

  5  

 

 

e. No Conflicts. The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a material adverse effect). All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof. The Company is not in violation of the listing requirements of the OTC marketplace (the “OTC MARKETS”) and does not reasonably anticipate that the Common Stock will be delisted by the OTC Markets in the foreseeable future, nor are the Company’s securities “chilled” by DTC. The Company and its subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

 

f. Absence of Litigation. Except as disclosed in the Company’s public filings, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its subsidiaries, threatened against or affecting the Company or any of its subsidiaries, or their officers or directors in their capacity as such, that could have a material adverse effect. Schedule 3(f) contains a complete list and summary description of any pending or, to the knowledge of the Company, threatened proceeding against or affecting the Company or any of its subsidiaries, without regard to whether it would have a material adverse effect. The Company and its subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

 

g. Acknowledgment Regarding Buyer’ Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting solely in the capacity of arm’s length purchasers with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by the Buyer or any of its respective representatives or agents in connection with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to the Buyer’ purchase of the Securities. The Company further represents to the Buyer that the Company’s decision to enter into this Agreement has been based solely on the independent evaluation of the Company and its representatives.

 

  6  

 

 

h. No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to the Buyer. The issuance of the Securities to the Buyer will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval provisions applicable to the Company or its securities.

 

i. Title to Property. The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(i) or such as would not have a material adverse effect. Any real property and facilities held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as would not have a material adverse effect.

 

j. Bad Actor. No officer or director of the Company would be disqualified under Rule 506(d) of the Securities Act as amended on the basis of being a “bad actor” as that term is established in the September 19, 2013 Small Entity Compliance Guide published by the Securities and Exchange Commission.

 

k. Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default under the Note.

 

4. COVENANTS.

 

a. Expenses. At the Closing, the Company shall reimburse Buyer for expenses incurred by them in connection with the negotiation, preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith (“Documents”), including, without limitation, reasonable attorneys’ and consultants’ fees and expenses, transfer agent fees, fees for stock quotation services, fees relating to any amendments or modifications of the Documents or any consents or waivers of provisions in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of restructuring the transactions contemplated by the Documents. When possible, the Company must pay these fees directly, otherwise the Company must make immediate payment for reimbursement to the Buyer for all fees and expenses immediately upon written notice by the Buyer or the submission of an invoice by the Buyer.

 

  7  

 

 

b. Listing. The Company shall promptly secure the listing of the Conversion Shares upon each national securities exchange or automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance) and, so long as the Buyer owns any of the Securities, shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of all Conversion Shares from time to time issuable upon conversion of the Note. The Company will obtain and, so long as the Buyer owns any of the Securities, maintain the listing and trading of its Common Stock on the OTC MARKETS or any equivalent replacement market, the Nasdaq stock market (“Nasdaq”), the New York Stock Exchange (“NYSE”), or the American Stock Exchange (“AMEX”) and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the Financial Industry Regulatory Authority (“FINRA”) and such exchanges, as applicable. The Company shall promptly provide to the Buyer copies of any notices it receives from the OTC MARKETS and any other markets on which the Common Stock is then listed regarding the continued eligibility of the Common Stock for listing on such markets.

 

c. Corporate Existence. So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded corporation whose Common Stock is listed for trading on the OTC MARKETS, Nasdaq, NYSE or AMEX.

 

d. No Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable to the Company or its securities.

 

e. Restricted Shares. The Company shall issue 90,000 of restricted Common Stock to the Buyer as additional consideration for the purchase of the Note.

 

f. Breach of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an event of default under the Note.

 

5. Governing Law; Miscellaneous.

 

a. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county of New York. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Company and Buyer waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement or any other Transaction Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

  8  

 

 

b. Counterparts; Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering this Agreement.

 

c. Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

 

d. Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

 

e. Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

 

  9  

 

 

f. Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, (iv) via electronic mail or (v) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received) or delivery via electronic mail, or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

 

  If to the Company, to:
    Tauriga Sciences, Inc.
    555 Madison Avenue, 5th Floor New York, NY 10022
    Attn: Seth M. Shaw, CEO

 

  If to the Buyer:
    GS Capital Partners, LLC
    30 Washington Street, Suite 5L Brooklyn, NY 11201
    Attn: Gabe Sayegh

 

Each party shall provide notice to the other party of any change in address.

 

g. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other. Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities in a private transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

 

h. Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

i. Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

 

j. Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

  10  

 

 

k. No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

l. Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

 

  11  

 

 

IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

 

Tauriga Sciences, Inc.

 

By:  
Name: Seth M. Shaw  
Title: CEO  

 

GS CAPITAL PARTNERS, LLC.

 

By:    
Name: Gabe Sayegh  
Title: President  

 

AGGREGATE SUBSCRIPTION AMOUNT:

 

Aggregate Principal Amount of Note: $33,000.00  
Aggregate Purchase Price:    
Note 1: $33,000.00 less $3,000.00 in OID    

 

  12  

 

 

EXHIBIT A

144 NOTE - $33,000.00

 

  13  

 

 

Exhibit 4.2

 

THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN AND WILL NOT BE REGISTERED WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE PURSUANT TO AN EXEMPTION FROM REGISTRATION PROVIDED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER (THE “1933 ACT”)

 

US $33,000.00

 

TAURIGA SCIENCES, INC.

8% CONVERTIBLE REDEEMABLE NOTE

DUE JUNE 4, 2021

 

FOR VALUE RECEIVED, Tauriga Sciences, Inc. (the “Company”) promises to pay to the order of GS CAPITAL PARTNERS, LLC and its authorized successors and permitted assigns (“Holder”), the aggregate principal face amount of Thirty Three Thousand Dollars exactly (U.S. $33,000.00) on June 4, 2021 (“Maturity Date”) and to pay interest on the principal amount out- standing hereunder at the rate of 8% per annum commencing on June 4, 2020. The Company acknowledges this Note was issued with a $3,000 original issue discount (OID) and as such the purchase price was $30,000.00. The interest will be paid to the Holder in whose name this Note is registered on the records of the Company regarding registration and transfers of this Note. The principal of, and interest on, this Note are payable at 30 Washington Street, Suite 5L, Brooklyn, NY 11201, initially, and if changed, last appearing on the records of the Company as designated in writing by the Holder hereof from time to time. The Company will pay each interest payment and the outstanding principal due upon this Note before or on the Maturity Date, less any amounts required by law to be deducted or withheld, to the Holder of this Note by check or wire transfer addressed to such Holder at the last address appearing on the records of the Company. The for- warding of such check or wire transfer shall constitute a payment of outstanding principal hereun- der and shall satisfy and discharge the liability for principal on this Note to the extent of the sum represented by such check or wire transfer. Interest shall be payable in Common Stock (as defined below) pursuant to paragraph 4(b) herein.

 

This Note is subject to the following additional provisions:

 

1. This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the Holder surrendering the same. No ser- vice charge will be made for such registration or transfer or exchange, except that Holder shall pay any tax or other governmental charges payable in connection therewith.

 

sms

 

Initials

 

 

 

 

2. The Company shall be entitled to withhold from all payments any amounts required to be withheld under applicable laws.

 

3. This Note may be transferred or exchanged only in compliance with the Securities Act of 1933, as amended (“Act”) and applicable state securities laws. Any attempted transfer to a non-qualifying party shall be treated by the Company as void. Prior to due present- ment for transfer of this Note, the Company and any agent of the Company may treat the person in whose name this Note is duly registered on the Company’s records as the owner hereof for all other purposes, whether or not this Note be overdue, and neither the Company nor any such agent shall be affected or bound by notice to the contrary. Any Holder of this Note electing to exercise the right of conversion set forth in Section 4(a) hereof, in addition to the requirements set forth in Section 4(a), and any prospective transferee of this Note, also is required to give the Company written confirmation that this Note is being converted (“Notice of Conversion”) in the form an- nexed hereto as Exhibit A. The date of receipt (including receipt by telecopy) of such Notice of Conversion shall be the Conversion Date.

 

4. (a) The Holder of this Note is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of this Note then out- standing into shares of the Company’s common stock (the “Common Stock”) at a price (“Conver- sion Price”) for each share of Common Stock equal to 65% of the lowest daily VWAP of the Common Stock as reported on the National Quotations Bureau OTC Markets exchange which the Company’s shares are traded or any exchange upon which the Common Stock may be traded in the future (“Exchange”), for the twenty prior trading days including the day upon which a Notice of Conversion is received by the Company or its transfer agent (provided such Notice of Conver- sion is delivered by fax or other electronic method of communication to the Company or its transfer agent after 4 P.M. Eastern Standard or Daylight Savings Time if the Holder wishes to include the same day closing price). If the shares have not been delivered within 3 business days, the Notice of Conversion may be rescinded. Such conversion shall be effectuated by the Company delivering the shares of Common Stock to the Holder within 3 business days of receipt by the Company of the Notice of Conversion. Accrued but unpaid interest shall be subject to conversion. No fractional shares or scrip representing fractions of shares will be issued on conversion, but the number of shares issuable shall be rounded to the nearest whole share. To the extent the Conversion Price of the Company’s Common Stock closes below the par value per share, the Company will take all steps necessary to solicit the consent of the stockholders to reduce the par value to the lowest value possible under law. The Company agrees to honor all conversions submitted pending this increase. In the event the Company experiences a DTC “Chill” on its shares, the conversion price shall be decreased to 55% instead of 65% while that “Chill” is in effect. In no event shall the Holder be allowed to effect a conversion if such conversion, along with all other shares of Company Common Stock beneficially owned by the Holder and its affiliates would exceed 9.9% of the outstanding shares of the Common Stock of the Company. All the terms set forth herein, including but not limited to interest rate, prepayment terms, conversion discount or lookback period will be adjusted downward (i.e. for the benefit of the Holder) if the Company offers a more favorable conversion discount (whether via interest, rate OID or otherwise) or lookback period to another party or oth- erwise grants any more favorable terms to any third party than those contained herein while this note is in effect.

 

sms

 

Initials

 

2

 

 

(b) Interest on any unpaid principal balance of this Note shall be paid at the rate of 8% per annum. Interest shall be paid by the Company in Common Stock (“Interest Shares”). Holder may, at any time, send in a Notice of Conversion to the Company for Interest Shares based on the formula provided in Section 4(a) above. The dollar amount converted into Interest Shares shall be all or a portion of the accrued interest calculated on the unpaid principal balance of this Note to the date of such notice.

 

(c) During the first six months this Note is in effect, the Company may redeem this Note by paying to the Holder an amount as follows: (i) if the redemption is within the first 90 days this Note is in effect, then for an amount equal to 120% of the unpaid principal amount of this Note along with any interest that has accrued during that period, (ii) if the redemption is after the 91st day this Note is in effect, but less than the 180th day this Note is in effect, then for an amount equal to 133% of the unpaid principal amount of this Note along with any accrued interest. This Note may not be redeemed after 180 days. The redemption must be closed and paid for within 3 business days of the Company sending the redemption demand or the redemption will be invalid and the Company may not redeem this Note. Such redemption must be closed and funded within 3 days of giving notice of redemption of the right to redeem shall be null and void.

 

(d) Upon (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, other than a forward or reverse stock split or stock dividend, or (iii) any consolidation or merger of the Com- pany with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) (each of items (i), (ii) and (iii) being referred to as a “Sale Event”), then, in each case, the Company shall, upon request of the Holder, redeem this Note in cash for 150% of the principal amount, plus accrued but unpaid interest through the date of re- demption, or at the election of the Holder, such Holder may convert the unpaid principal amount of this Note (together with the amount of accrued but unpaid interest) into shares of Common Stock immediately prior to such Sale Event at the Conversion Price.

 

(e) In case of any Sale Event (not to include a sale of all or substantially all of the Company’s assets) in connection with which this Note is not redeemed or converted, the Com- pany shall cause effective provision to be made so that the Holder of this Note shall have the right thereafter, by converting this Note, to purchase or convert this Note into the kind and number of shares of stock or other securities or property (including cash) receivable upon such reclassifica- tion, capital reorganization or other change, consolidation or merger by a holder of the number of shares of Common Stock that could have been purchased upon exercise of the Note and at the same Conversion Price, as defined in this Note, immediately prior to such Sale Event. The forego- ing provisions shall similarly apply to successive Sale Events. If the consideration received by the holders of Common Stock is other than cash, the value shall be as determined by the Board of Directors of the Company or successor person or entity acting in good faith.

 

sms

 

Initials

 

3

 

 

5. No provision of this Note shall alter or impair the obligation of the Com- pany, which is absolute and unconditional, to pay the principal of, and interest on, this Note at the time, place, and rate, and in the form, herein prescribed.

 

6. The Company hereby expressly waives demand and presentment for pay- ment, notice of non-payment, protest, notice of protest, notice of dishonor, notice of acceleration or intent to accelerate, and diligence in taking any action to collect amounts called for hereunder and shall be directly and primarily liable for the payment of all sums owing and to be owing hereto.

 

7. The Company agrees to pay all costs and expenses, including reasonable attorneys’ fees and expenses, which may be incurred by the Holder in collecting any amount due under this Note.

 

8. If one or more of the following described “Events of Default” shall occur:

 

(a) The Company shall default in the payment of principal or interest on this Note or any other note issued to the Holder by the Company; or

 

(b) Any of the representations or warranties made by the Company herein or in any certificate or financial or other written statements heretofore or hereafter furnished by or on behalf of the Company in connection with the execution and delivery of this Note, or the Securities Purchase Agreement under which this note was issued shall be false or misleading in any respect; or

 

(c) The Company shall fail to perform or observe, in any respect, any covenant, term, provision, condition, agreement or obligation of the Company under this Note or any other note issued to the Holder; or

 

(d) The Company shall (1) become insolvent; (2) admit in writing its inability to pay its debts generally as they mature; (3) make an assignment for the benefit of creditors or commence proceedings for its dissolution; (4) apply for or consent to the appointment of a trustee, liquidator or receiver for its or for a substantial part of its property or business; (5) file a petition for bankruptcy relief, consent to the filing of such petition or have filed against it an involuntary petition for bankruptcy relief, all under federal or state laws as applicable; or

 

(e) A trustee, liquidator or receiver shall be appointed for the Company or for a substantial part of its property or business without its consent and shall not be discharged within sixty (60) days after such appointment; or

 

sms

 

Initials

 

4

 

 

(f) Any governmental agency or any court of competent jurisdiction at the in- stance of any governmental agency shall assume custody or control of the whole or any substantial portion of the properties or assets of the Company; or

 

(g) One or more money judgments, writs or warrants of attachment, or similar process, in excess of fifty thousand dollars ($50,000) in the aggregate, shall be entered or filed against the Company or any of its properties or other assets and shall remain unpaid, unvacated, unbonded or unstayed for a period of fifteen (15) days or in any event later than five (5) days prior to the date of any proposed sale thereunder; or

 

(h) The Company shall have defaulted on or breached any term of any other note of similar debt instrument into which the Company has entered and failed to cure such default within the appropriate grace period; or

 

(i) The Company shall have its Common Stock delisted from an exchange (in- cluding the OTC Market Exchange) or, if the Common Stock trades on an exchange, then trading in the Common Stock shall be suspended for more than 10 consecutive days or ceases to file its 1934 act reports with the SEC;

 

(j) If a majority of the members of the Board of Directors of the Company on the date hereof are no longer serving as members of the Board;

 

(k) The Company shall not deliver to the Holder the Common Stock pursuant to paragraph 4 herein without restrictive legend within 3 business days of its receipt of a Notice of Conversion; or

 

(l) The Company shall not replenish the reserve set forth in Section 12, within 3 business days of the request of the Holder.

 

(m) The Company shall not be “current” in its filings with the Securities and Exchange Commission;

 

(n) The Company shall lose the “bid” price for its stock in a market (including the OTC marketplace or other exchange); or

 

Then, or at any time thereafter, unless cured within 5 days, and in each and every such case, unless such Event of Default shall have been waived in writing by the Holder (which waiver shall not be deemed to be a waiver of any subsequent default) at the option of the Holder and in the Holder’s sole discretion, the Holder may consider this Note immediately due and payable, without present- ment, demand, protest or (further) notice of any kind (other than notice of acceleration), all of which are hereby expressly waived, anything herein or in any note or other instruments contained to the contrary notwithstanding, and the Holder may immediately, and without expiration of any period of grace, enforce any and all of the Holder’s rights and remedies provided herein or any other rights or remedies afforded by law. Upon an Event of Default, interest shall accrue at a default interest rate of 24% per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. In the event of a breach of Section 8(k) the penalty shall be $250 per day the shares are not issued beginning on the 4th day after the conversion notice was delivered to the Company. This penalty shall increase to $500 per day beginning on the 10th day. The penalty for a breach of Section 8(n) shall be an increase of the outstanding principal amounts by 20%. In case of a breach of Section 8(i), the outstanding principal due under this Note shall increase by 50%. If this Note is not paid at maturity, the outstanding principal due under this Note shall increase by 10%. Further, if a breach of Section 8(m) occurs or is continuing after the 6 month anniversary of the Note, then the Holder shall be entitled to use the lowest closing bid price during the delinquency period as a base price for the conversion. For example, if the lowest closing bid price during the delinquency period is $0.01 per share and the conversion dis- count is 50% the Holder may elect to convert future conversions at $0.005 per share.

 

sms

 

Initials

 

5

 

 

If the Holder shall commence an action or proceeding to enforce any provisions of this Note, in- cluding, without limitation, engaging an attorney, then if the Holder prevails in such action, the Holder shall be reimbursed by the Company for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding.

 

Make-Whole for Failure to Deliver Loss. At the Holder’s election, if the Company fails for any reason to deliver to the Holder the conversion shares by the by the 3rd business day following the delivery of a Notice of Conversion to the Company and if the Holder incurs a Failure to Deliver Loss, then at any time the Holder may provide the Company written notice indicating the amounts payable to the Holder in respect of the Failure to Deliver Loss and the Company must make the Holder whole as follows:

 

Failure to Deliver Loss = [(High trade price at any time on or after the day of exercise) x (Number of conversion shares)]

 

The Company must pay the Failure to Deliver Loss by cash payment, and any such cash payment must be made by the third business day from the time of the Holder’s written notice to the Com- pany.

 

9. In case any provision of this Note is held by a court of competent jurisdic- tion to be excessive in scope or otherwise invalid or unenforceable, such provision shall be ad- justed rather than voided, if possible, so that it is enforceable to the maximum extent possible, and the validity and enforceability of the remaining provisions of this Note will not in any way be affected or impaired thereby.

 

10. Neither this Note nor any term hereof may be amended, waived, discharged or terminated other than by a written instrument signed by the Company and the Holder.

 

11. The Company represents that it is not a “shell” issuer and has never been a “shell” issuer or that if it previously has been a “shell” issuer that at least 12 months have passed since the Company has reported form 10 type information indicating it is no longer a “shell issuer. Further. The Company will instruct its counsel to either (i) write a 144 opinion to allow for sala- bility of the conversion shares or (ii) accept such opinion from Holder’s counsel.

 

sms

 

Initials

 

6

 

 

12. The Company shall issue irrevocable transfer agent instructions reserving 3,678,000 shares of its Common Stock for conversions under this Note equal to two and a half times the discounted value of the Note (the “Share Reserve”). Upon full conversion of this Note, any shares remaining in the Share Reserve shall be cancelled. The Company shall pay all transfer agent costs associated with issuing and delivering the share certificates to Holder. If such amounts are to be paid by the Holder, it may deduct such amounts from the Conversion Price. The company should at all times reserve a minimum of two and a half times the amount of shares required if the note would be fully converted. The Holder may reasonably request increases from time to time to reserve such amounts. The Company will instruct its transfer agent to provide the outstanding share information to the Holder in connection with its conversions.

 

13. The Company will give the Holder direct notice of any corporate actions, including but not limited to name changes, stock splits, recapitalizations etc. This notice shall be given to the Holder as soon as possible under law.

 

14. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable provision shall automatically be revised to equal the maximum rate of interest or other amount deemed interest permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it will not seek to claim or take advantage of any law that would prohibit or forgive the Company from paying all or a portion of the principal or interest on this Note.

 

15. This Note shall be governed by and construed in accordance with the laws of New York applicable to contracts made and wholly to be performed within the State of New York and shall be binding upon the successors and assigns of each party hereto. The Holder and the Company hereby mutually waive trial by jury and consent to exclusive jurisdiction and venue in the courts of the State of New York or in the Federal courts sitting in the county or city of New York. This Agreement may be executed in counterparts, and the facsimile transmission of an executed counterpart to this Agreement shall be effective as an original.

 

sms

 

Initials

 

7

 

 

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed by an officer thereunto duly authorized.

 

Dated: June 5, 2020  

 

  TAURIGA SCIENCES, INC.
   
  By:
  Title: Chief Executive Officer – Seth M. Shaw

 

 

Initials

 

8

 

 

EXHIBIT A

 

NOTICE OF CONVERSION

 

(To be Executed by the Registered Holder in order to Convert the Note)

 

The undersigned hereby irrevocably elects to convert $                      of the above Note into              Shares of Common Stock of Tauriga Sciences, Inc. (“Shares”) according to the conditions set forth in such Note, as of the date written below.

 

If Shares are to be issued in the name of a person other than the undersigned, the undersigned will pay all transfer and other taxes and charges payable with respect thereto.

 

Date of Conversion: ________________________________________________________________

Applicable Conversion Price: _________________________________________________________

Signature: ________________________________________________________________________

[Print Name of Holder and Title of Signer]

Address: ___________________________________________________________________________

____________________________________________________________________________

 

SSN or EIN: _________________________

Shares are to be registered in the following name: ____________________________________________________

 

Name: ___________________________________________________________________________

Address: _________________________________________________________________________

Tel: _________________________________________

Fax: _________________________________________

SSN or EIN: __________________________________

 

Shares are to be sent or delivered to the following account:

 

Account Name: ___________________________________________________________________

Address: ___________________________________________________________________________

 

 

Initials

 

9

 

Exhibit 10.1

 

 

381 SOUTH CENTRAL

AVE. OV I E D O, F L 3 2 7 6 5

 

GO-TO-MARKET DIRECT TO DISTRIBUTOR AGREEMENT

 

All changes or additions to the agreement will be considered binding when agreed upon by Mr. Checkout and the Company through any form of written consent, including email communication.

 

By signing below, the Company agrees to any services agreed upon by both parties in writing hereafter. The Company also agrees to the disclaimers below.

 

ROLES & RESPONSIBILITIES:

 

1. Mr. Checkout will be responsible for creating relationship opportunities with its network of distributors.
2. Mr. Checkout will build a client dashboard to track initial go-to-market strategy.
3. Mr. Checkout will organize and handle initial education and introductions to an initial group of 3-5 distributors.
4. Mr. Checkout will relay sales to new distributors once initial test group of distributors have had two turns on the initial orders.
5. Company will report sales using template provided and pay commission every three (3) months after the execution of this agreement. Commission and reporting is due within thirty (30) days after the close of each quarter. If reporting of sales is not completed once a quarter regardless of sales, this agreement will be considered terminated by the Company.
6. Company will be expected to email purchase orders from contacts introduced by Mr. Checkout within ten (10) business days after the initial purchase order is received.
7. Company will be expected to contact all distributors, buyers and wholesalers introduced by Mr. Checkout within five (5) business days after the initial introduction. If Company is unable to contact any distributor after fourteen (14) days, Company must inform distribution manager accordingly.
8. Company will inform Mr. Checkout of any alterations to product lines, new lines and current distributors.
9. If Company retains a new staff member, Company is responsible for introducing that new staff member who will be responsible for handling the relationship to the distributors who have already been introduced.
   

DISCLAIMERS:

 

1. Confidentiality: Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose. Parties shall not use for any purpose other than as provided for in this Agreement share any contact information to any other Party pursuant to this Agreement, except for the purposes of introducing opportunities for sales and distribution.
2. Collections Disclaimer: In disputes for breach of warranty and/or breach of agreement, the prevailing party shall be entitled to its attorney’s fees and costs. This agreement shall be interpreted under the laws of the State of Florida.
3. Term of Agreement: This Agreement shall continue in full force and effect for a term of two (2) years from the date of execution and shall be binding upon and inure to the benefit of the parties hereto and their successors and assigns including purchasers of Company’s assets.
4. Arbitration: All disputes, controversies or differences that may arise between the parties out of or in relation to or in connection with this Agreement, or the breach hereof, shall be finally settled exclusively by binding arbitration. Except in the case of a breach of this Agreement by Mr. Checkout, the Company hereby agrees to indemnify and hold Mr. Checkout harmless from and against any claim, demand, loss, financial or otherwise, damage, liability or cost, including legal fees and expenses. Arbitration will be in accordance with the United States Arbitration Act (Title 9, U.S. Code). Any controversy concerning whether an issue is arbitrable shall be determined by the arbitrators.
5. Termination: The Company may terminate this contract at any time for any reason by giving at least thirty (30) days notice in writing to Mr. Checkout. If the contract is terminated by the Company, Mr. Checkout will have considered the retainer on commissions as earned for the work completed as of the date of termination. Mr. Checkout may terminate this contract and refund the retainer at any time for any reason by giving at least thirty (30) days notice in writing to Company.

 

 

    Page 1 of 2
 

 

COMPENSATION:

 

1a. Commission Schedule: Mr. Checkout shall earn a standard commission of 5% unless sales goals specified below are met. Other than standard Products, Programs, and Services, compensation may be amended as agreed to in writing by both parties on a case-by-case basis prior to product presentation to account. The term on commission shall not exceed twenty four (24) months from the introduction of the distributor.

 

1b. Retainer on Commission: Company would pay a one time $5,000 retainer on commission against the first $100,000 in sales. Subsequent commissions shall be paid to Mr. Checkout via check or bank wire during the first thirty days (30) of the subsequent quarter after the advance once retainer has been met and exceeded. Commission will not be paid until the retainer has been met.

 

1c. Retainer Guarantee: Retainer on commission will be fully refunded in the case where purchases from distributors introduced by Mr. Checkout to the Company fail to justify $5,000 in commissions within the term of this agreement, in which case Mr. Checkout shall fully refund the retainer.

 

 

● Commissions on all sales under $500,000 per 12 month period are 5%, commissions shall be reduced from 5% to 4% after $500,000 net invoice sales, commissions shall be reduced from 4% to 3% after $1,000,000 in net invoice sales.

 

● Commissions on orders shall be considered earned to Mr. Checkout once the Company receives full payment on the invoice price for any particular order from any business introduced by Mr. Checkout. Existing Customers shall remain exempt from any due commissions, for which no commission shall be due Mr. Checkout.

 

● Commissions shall be computed on the net invoice price of the product. The “net invoice price” shall be computed by deducting from the gross sales price, all taxes, freight, insurance charges, credits (arising from returns or other adjustments), discounts, rebates or allowances of any kind.

 

     
Company Signature   Date: 6/29/20
Name, Title: Seth Shaw, CEO    
     
     
Mr. Checkout Signature   Date: 6/29/20
Name, Title: Joel Goldstein, President    

 

    Page 2 of 2

 

 

Exhibit 10.2

 

PRODUCT PLACEMENT MEMBERSHIP AGREEMENT

 

This Product Placement Membership Agreement (“Agreement”), dated as of July 10th, 2020 (the “Effective Date”), is entered into by and between TAURIGA SCIENCES, INC. a Florida corporation (“Client”), and KushCo Holdings, Inc., a Nevada corporation (“Placement Agent”), collectively referred to as the “Parties” and each a “Party” and is based upon the following facts and circumstances:

 

WHEREAS, Client is in the business of manufacturing and distributing certain legally compliant hemp derived products (the “Products”);

 

WHEREAS, Placement Agent is in the business of providing certain services, including without limitation, retail activation, product incubation, branding and marketing solutions, and sales management of certain products (the “Services”), and NOW, THEREFORE, in consideration of the mutual covenants herein contained, Client and Placement Agent hereby agree as follows:

 

1. Defined Terms. In addition to other terms defined elsewhere in this Agreement, the following terms shall have the following meanings:

 

1.1 “Affiliate” shall mean, any individual, corporation, company, partnership, joint venture, unincorporated organization or other entity directly or indirectly controlling, controlled by or under common control with the applicable Party.

 

1.2 “Transaction(s)” shall mean any sale, exchange, transfer, conveyance, option to purchase the Products or other products sold and distributed by the Client to a third-party or third-parties utilizing any of the Service(s) provided by Placement Agent.

 

2. Fees. If Client or any Affiliate of Client consummates any Transaction(s) with a third-party for the Product(s), Placement Agent shall be paid a fee equal to ten and 00/100 percent (10.00%) of the total gross sales for such Transaction(s) for any and all Products or other products sold and distributed by Client to a third-party or third-parties utilizing any of the Service(s) provided by Placement Agent (each the “Placement Fee” and collectively, the “Placement Fees”). The Placement Fee shall be earned as of the date of the respective Transaction and shall be paid in cash by Client to Placement Agent on a monthly basis and no later than the last calendar day of each calendar month.

 

3. Monthly Reporting & Audit. Client shall provide Placement Agent monthly sales statements illustrating the number of Transaction(s) completed during each calendar month, and such other information relating to this Agreement as may be reasonably requested by the Placement Agent. Client shall provide Placement Agent with a monthly rolling forecast of estimated Transaction(s) for the following month. The forecast is for planning purposes only and is not binding. Placement Agent will have the right, upon reasonable request, to audit and review the books and records of Client sufficient to review and confirm the Placement Fee(s). Any such audit will be conducted at Placement Agent’s expense and at such times and in such a manner as to not unreasonably interfere with Client’s normal operations. Client shall maintain all such books and records for a period of three (3) years after the closing of any Transaction(s).

 

Page 1 of 9

 

 

4. Placement Agent’s Role. Client hereby acknowledges and agrees that (a) Placement Agent may find, procure and introduce Client to certain entities or persons or their Affiliate(s) that Placement Agent has identified that may be willing to entering into the Transaction with Client, (b) Client has at all times been (or will be) represented by legal counsel of its own choice; and (c) nothing in this Agreement shall restrict Placement Agent from providing the same or similar services to other parties.

 

5. Term; Termination & Recognition. The term of this Agreement commences on the Effective Date and continues for a period of two (2) years, unless earlier terminated as provided under this Agreement. Placement Agent may terminate this Agreement upon sixty (60) days’ prior written notice to the Client. Termination or expiration of this Agreement for any reason will not negate any obligation of the Client, which arose prior to the effective date of such termination, including without limitation Client’s obligation to compensate Placement Agent in accordance with the payment terms agreed upon for all Services performed prior to termination or expiration. Notwithstanding anything to the contrary, if within two (2) years after the expiration or earlier termination of this this Agreement a Transaction is completed, then Client shall pay Placement Agent the Placement Fee in accordance with the provisions of this Agreement on account of such Transaction(s).

 

6. Notices. Any notices or other communications between Client and Placement Agent may be given at the addresses set forth below:

 

  To Placement Agent: KushCo Holdings, Inc.,
    6261 Katella Ave., Suite 250
    Cypress, CA 90630
    Attn: Legal@Kushco.com
     
  To Client: Tauriga Sciences, Inc.
    555 Madison Avenue, 5th Foor
    New York, NY 10022
    Attn: Seth M. Shaw
    Email: sshaw@tauriga.com
    Tel. (917) 796 9926

 

Any notice or communication under this Agreement must be in writing and sent via personal delivery, overnight courier service, email, or certified or registered mail, postage prepaid, return receipt requested and addressed to the to the address stated above or to another address as that Party may subsequently designate by notice and shall be deemed given on the date of delivery. Any such notice shall be deemed delivered and given as of the date so delivered, if delivered personally, the following business day if delivered by overnight courtier or email, or seventy-two (72) hours after deposit in a regularly maintained receptacle for the deposit of United States mail, postage paid, addressed and sent as aforesaid.

 

Page 2 of 9

 

 

7. Liability for Due Diligence Costs. All reasonable out-of-pocket costs incurred by the Client hereto and/or their respective affiliates in connection with the Transaction(s) (including, without limitation, due diligence expenses, legal fees, costs of travel, costs of third party reports, preparation and negotiation of this Agreement and the documents necessary to consummate the Transaction(s), formation of entities intended to be used in connection with the Transaction(s), transfer taxes, conveyance taxes, intangible taxes and other similar taxes, escrow fees, Placement Fees and any other expenses of any kind or nature incurred in connection with the Transaction(s) will be paid by Client. To the extent that any such costs are incurred by Placement Agent on behalf of Client, Placement Agent shall promptly reimburse Placement Agent for the cost thereof.

 

8. Late Fees. In the event Client fails to make any payments when due under this Agreement then Client will be charged a late fee of five percent (5%) of the outstanding balance per month or the maximum rate allowed by applicable law, whichever is lower. Placement Agent shall recover any out-of-pocket expenses incurred in collecting payments due, including, without limitation, any bank charges for returned checks and attorneys’ fees. In the event of any late payment by Client that is not cured within five (5) days from the date of notice thereof, Placement Agent may decline to offer any additional Service(s) until all amounts due and late fees are paid in full, without in any way affecting its rights under this Agreement. Placement Agent may enforce the foregoing rights without waiving any and all other rights or remedies it may have for any breach of this Agreement.

 

9. Independent Contractor Status. Client and Placement Agent acknowledge and declare that neither Party intends to create an employee/employer relationship, nor an agent/principal relationship, by this Agreement. It is the Parties intention that the Placement Agent shall have an independent contractor status and not be an employee for any purposes including, but not limited to, the application of the Federal Insurance Contribution Act, Social Security Act, Federal Unemployment Tax Act, provisions of the Internal Revenue Code, State Revenue and Taxation Code relating to income tax withholding at the source of income, Workers’ Compensation Insurance Code 401(k) and other benefit payments and third party liability claims. Placement Agent will retain sole and absolute discretion in the manner and means of carrying out their activities and responsibilities under this Agreement. This Agreement will not be considered or construed to be a partnership or joint venture and neither party shall not be liable for any obligations incurred by the other unless specifically authorized in writing by the both Parties.

 

10. Insurance. During the term of this Agreement, Client shall, at its own expense, maintain and carry insurance in full force and effect which includes, but is not limited to, commercial general liability in a sum reasonably appropriate for Client’s industry and size with financially sound and reputable insurers. Upon Placement Agent’s request, Client shall provide Placement Agent with a certificate of insurance from Client’s insurer evidencing the insurance coverage specified in this Agreement. Client shall provide Placement Agent with thirty (30) days’ advance written notice in the event of a cancellation or material change in Client’s insurance policy.

 

Page 3 of 9

 

 

11. Disclaimer of Warranties; Limitation of Liability. Placement Agent makes no warranties, whether written, oral, or implied. Placement Agent expressly disclaims the making of, and Client acknowledges that it has not received, any warranty or guarantee, express or implied or statutory, as to the past, present or future performance of the Services or the potential performance or success of a Transaction. Furthermore, Client acknowledges that Placement Agent is not obligated to independently verify the accuracy or the completeness of the information provided to Placement Agent and/or any party entering into a Transaction with Client, and that Placement Agent is not responsible for any inaccurate or incomplete data provided by such parties. In no event shall the Placement Agent be liable, whether in contract or tort (including negligence or product liability), for any of the following arising out of or concerning this Agreement, however caused: consequential, special, moral, incidental, indirect, reliance, punitive or exemplary damages, loss of goodwill, profits, use, opportunities, revenue or savings; business interruption; or loss; regardless of (a) whether such damages were foreseeable, (b) whether the Placement Agent was advised of the possibility of such damages, (c) the legal or equitable theory (contract, tort or otherwise) upon which the claim is based, and (d) the failure of any agreed or other remedy of its essential purpose. In no event shall the Placement Agent’s aggregate liability arising out of or related to this Agreement or its subject matter, for breach of contract, tort (including negligence or product liability) or otherwise, exceed the total amounts paid to the Placement Agent by Client for the Services sold hereunder.

 

12. Indemnity. Client hereby assumes all liability for, and shall defend (if required by Placement Agent and with counsel acceptable to Placement Agent), indemnify, defend, and hold Placement Agent and its affiliated companies, and their directors, officers, employees, shareholders, agents, affiliates, successors and assigns, harmless from and against any and all liabilities, claims, demands, suits, actions, proceedings, judgments, losses, damages, penalties, fines or other sanctions, costs or expenses of any nature whatsoever (including, without limitation, attorneys’ fees and expenses through all appeals), whether arising directly or indirectly or whether in contract, tort (including negligence), strict liability, product liability or otherwise, arising from or out of: (i) Client’s acts or omissions under this Agreement, including but not limited to claims of product liability; (ii) the manufacture, delivery, or other disposition, provisioning, or supply of any Product, if the claim is a result of Client’s actions or non-actions; (iii) product recalls related to manufacturing, delivery, or other disposition or safety of any Products or other products distributed by or through the Client, whether or not initiated by Client; (iv) any breach of representation, warranty, covenant or agreement on the part of Client under this Agreement; (v) any other failure of Client to comply with its obligations hereunder; or (vi) any failure or alleged failure to comply with applicable federal or state laws or regulations (including those promulgated by the USDA, FDA, FTC and state agencies). The provisions of this section shall survive the expiration or termination of this Agreement. The Placement Agent shall notify Client promptly of any such suit, claim or proceeding and give Client authority, information, and reasonable assistance (at Client’s sole expense) for the defense of same, and Client shall pay all damages and costs awarded therein. If the Placement Agent is necessarily joined in a legal action, the Placement Agent may elect to be represented by Client’s selected legal counsel, provided that Client’s pays all legal fees (including attorneys’ fees) and expenses of the Placement Agent. Notwithstanding the foregoing, any settlement of such suit, claim or proceeding shall be subject to the Placement Agent’s consent, such consent not to be unreasonably withheld.

 

13. Publication. Placement Agent shall have the right to post, share, list or otherwise use, including, without limitation, in connection with the Placement Agent’s website, social media, print and marketing materials (collectively, “Use”) that Client is a member and/or customer of Placement Agent.

 

Page 4 of 9

 

 

14. Compliance with Laws. The Parties shall comply with all rules, orders, determinations, laws and ordinances of any federal, state or local authority having or exercising jurisdiction over Transaction or the subject matter of this Agreement, including, without limitation, laws proscribing discrimination in the sale of real property. Client is responsible for compliance with all licensing requirements necessary in connection with any and all Transaction(s). Client will comply with all applicable laws with regard to the manufacturing, production and sale of any Product(s) pursuant this Agreement, and will obtain, at its sole cost and expense, all necessary registrations, approvals, permits, and other authorizations needed, whether from regulatory authorities or otherwise, in connection with such activities. Client will not engage in any illegal or unethical practices in connection with the Service(s) offered hereunder. Client shall comply with all applicable laws, regulations and ordinances, including compliance and cooperation with IRS Form 8300, Report of Cash Payments Over $10,000 received in a trade or business.

 

15. Governing Law. The laws of the State of California shall govern the legality, validity and enforceability of this Agreement, the construction of its terms, conditions and covenants, and the interpretation of the rights and duties of Client and Placement Agent.

 

16. Waiver of Jury Trial; Attorney’s Fees. Each Party hereto hereby acknowledges and agrees that any controversy that may arise under this agreement is likely to involve complicated and difficult issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial by jury in respect of any legal action arising out of or relating to this agreement or the transactions contemplated hereby. Any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate, shall be determined by final, binding arbitration in Orange County, California before one (1) independent arbitrator; provided, however, that each Party retains its right to seek injunctive relief under applicable law in a state court located in Orange County, California. The arbitration shall be administered by JAMS pursuant to JAMS’ Streamlined Arbitration Rules and Procedures. Judgment on the award may be entered in any court having jurisdiction. The prevailing Party in any legal action (including arbitration) brought related to this Agreement, including exhibits, schedules, attachments, appendices, and/or amendments thereto shall be entitled to recover its legal expenses incurred in connection therewith, including without limitation reasonable attorney’s and expert witness fees and costs. The Parties hereby represent and acknowledge that they have been provided with the opportunity to discuss and review the terms of this Agreement with their respective attorneys before signing it and that they are freely and voluntarily signing this Agreement in exchange for the benefits provided herein. The Parties further represent and acknowledge that they have been provided a reasonable period of time within which to review the terms of this Agreement.

 

17. Miscellaneous.

 

17.1 Waiver. The waiver by either Party of the performance of any covenant, condition or promise shall not invalidate this Agreement, nor be considered a waiver of any other covenant, condition or promise. The waiver by either Party of the time for performing any act shall not constitute a waiver of time for performing any other act or an identical act required to be performed at a later time.

 

17.2 Amendments. All amendments and supplements to this Agreement must be in writing and executed by each party hereto.

 

Page 5 of 9

 

 

17.3 Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. However, this Agreement shall not be binding on a Party until all Parties have executed this document, either all on one document or in counterparts.

 

17.4 Entire Agreement. It is understood and acknowledged that there are no oral agreements between the Parties hereto affecting this Agreement and that this Agreement supersedes and cancels any and all previous negotiations, arrangements, agreements and understandings, if any, between the Parties hereto with respect to the subject matter thereof, and none thereof shall be used to interpret or construe this Agreement. This Agreement contains all of the terms, covenants, conditions, warranties and agreements of the Parties relating in any manner to the subject matter hereof and shall be considered to be the only agreement between the Parties hereto. All negotiations and oral agreements acceptable to both Parties have been merged into and are included herein. There are no other representations or warranties between the Parties, and all reliance with respect to representations is based totally upon the representations and agreements contained in this Agreement, if any.

 

17.5 Captions. The necessary grammatical changes required to make the provisions hereof apply either to corporations, limited liability companies, partnerships or individuals, men or women, as the case may require, shall in all cases be assumed as though in case fully expressed. The captions herein are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning hereof. If unenforceable, the remainder of this Agreement, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Agreement shall be valid and enforceable to the fullest extent possible permitted by law.

 

17.6 Assignment. The Parties agree that their rights and obligations under this Agreement may not be transferred or assigned without the prior written of the other Party, except that either Party shall be permitted, without the other Party’s consent, to assign or transfer this Agreement to any of its affiliates in connection with a merger or consolidation or a sale of all or substantially all of its assets. This Agreement shall be binding and inure to the benefit of the Parties and their respective legal representatives, heirs, administrators, executors, successors and permitted assigns.

 

17.7 Publicity. Neither Party shall issue a press release relating to the subject matter of this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld; provided, however, that Placement Agent shall be allowed to refer to Client as a customer of Placement Agent in general advertising and marketing initiatives. Placement Agent shall only have the right to use and market any participant/attendee data generated from the Services in an aggregated and personally unidentifiable form.

 

17.8 Confidential Information. It is expressly agreed that the identities of any individual or entity and any other third parties discussed and made available by Placement Agent in respect of the Transaction and any related business opportunity shall constitute “Confidential Information” and Client and its Affiliates shall not without the prior written consent of Placement Agent, to with withheld, conditioned or delayed in Placement Agent’s sole and absolute discretion: (a) directly or indirectly initiate, solicit, negotiate, contract or enter into any business transactions, agreements or undertakings with any such third party identified or introduced by Placement Agent; or (b) seek to by-pass, compete, avoid or circumvent the Placement Agent from any business opportunity that relates to the Transaction by utilizing any Confidential Information or by otherwise exploiting or deriving any benefit from the Confidential Information. Client each shall indemnify and hold Placement Agent harmless from and against any damage, loss, cost or expense (including without limitation, reasonable attorneys’ fees and costs incurred in the enforcement of the foregoing indemnity) arising out of a breach of this Section 17.8. This Section 17.8 shall survive the expiration or earlier termination of this Agreement.

 

Page 6 of 9

 

 

17.9 Electronic Signature. Signatures and initials required in this document may be executed via “wet” original handwritten signature or initials, or via electronic signature or mark, which shall be binding on the Parties as originals, and the executed signature pages may be delivered using pdf or similar file type transmitted via electronic mail, cloud based server, e- signature technology or other similar electronic means, and any such transmittal shall constitute delivery of the executed document for all purposes of this Agreement.

 

17.10 Authority. If either Party executes this Agreement as a partnership, corporation or limited liability company, then such Party and the persons and/or entities executing this Agreement represent and warrant that: (a) it is a duly organized and existing partnership, corporation or limited liability company, as the case may be, and is qualified to do business in the state in which the business is located; (b) such persons and/or entities executing this Agreement are duly authorized to execute and deliver this Agreement; and (c) this Agreement is binding in accordance with its terms.

 

[NO FURTHER TEXT ON THIS PAGE; SIGNATURES ON FOLLOWING PAGE]

 

Page 7 of 9

 

 

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

 

CLIENT

TAURIGA SCIENCES, INC

a Florida Corporation (C Corp.)

 

By: Tauriga Sciences, Inc.  
Name: Seth M. Shaw  
Title: Chief Executive Officer  

 

[SIGNATURES CONTINUED ON FOLLOWING PAGE]

 

Page 8 of 9

 

 

PLACEMENT AGENT

 

KUSHCO HOLDINGS, INC.

a Nevada limited liability company

 

By:    
Name: STEPHEN Christoffersen  
Title: Chief Financial Officer  

 

Page 9 of 9

 

 

Exhibit 99.1

 

Tauriga Sciences, Inc. and Mr. Checkout Distributors Sign Distribution Agreement to Launch Tauri-Gum Nationwide to as Many as 200,000 Retail Stores & Locations Press Release | 07/06/2020

 

This Launch of Tauri-Gum™ will be Supported by a National Network of More than 1,100 Independent Direct Store Delivery (“DSD”) Distributors

 

NEW YORK, NY, July 06, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced that it has entered into a Go-To-Market Distribution Agreement (the “Agreement”) with Oviedo, Florida based Mr. Checkout Distributors (“Mr. Checkout”). This Agreement (mutually executed on June 29, 2020) enables the Company to launch its flagship brand Tauri-Gum™, on a National level, through Mr. Checkout’s network of Independent DSD Distributors that service approximately 200,000 stores and retail locations across the United States. These stores include some of the most well-known convenience stores, gas station marts, and supermarket chains. Mr. Checkout has also provided the Company with inventory funding options, in anticipation of potential large sales volume.

 

The Tauri-Gum™ Brand is Comprised of: 6 distinct “functional” chewing gum flavors/versions: [3] CBD Isolate Infused (Pomegranate, Blood Orange, Mint), [2] CBG Isolate Infused (Peach-Lemon, Black Currant), and [1] Immune Booster / Vitamin C & Zinc Infused (Pear Bellini). CBD = Cannabidiol / CBG = Cannabigerol

 

Link - Corporate Website, Mr. Checkout Distributors: https://mrcheckout.net/retail-channel-partners/

 

Tauriga’s CEO Seth M. Shaw expressed, “The Company is excited to have this opportunity to launch its flagship Tauri-Gum™ brand on a national level, with the preeminent DSD Distributor in the United States. This is an important puzzle piece, with respect to the Company’s strategy to build Tauri-Gum™ into a major national brand. The Company is targeting the month of September 2020, to commence this National product launch.

 

Joel Goldstein, CEO of Mr. Checkout Distributors, stated, “After an extensive period of review, we decided to move forward with and include the Tauri-Gum™ product line as part of our product offerings. We were particularly impressed with the quality, taste, diversity, and packaging of this exciting new brand. We look forward to working with Tauriga Sciences, Inc. to make Tauri-Gum™ available to customers across the Country.

 

 

 

 

ABOUT TAURIGA SCIENCES, INC.

 

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com.

 

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives. The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.

 

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain. In addition, the Company operates a full-time E-Commerce fulfillment center located in LaGrangeville, New York.

 

ABOUT MR. CHECKOUT DISTRIBUTORS

 

Established 1989 | Mr. Checkout is a national group of Independent DSD Distributors, Full-Line Grocery Distributors and Wagon-Jobbers. We represent products in over 60 major retailers and manage 13 industry associations with over 150,000 independent retail members. Distributors, Wholesalers, and Retailers turn to Mr. Checkout to find the best-selling products, learn which categories are trending and discover what is the next hot new product. Please visit the following website: https://mrcheckout.net/dsd-distribution/

 

 

 

 

DISCLAIMER — Forward-Looking Statements

 

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

 

CONTACT INFORMATION

 

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY 10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

Cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website: www.tauriga.com

E-Commerce Website: www.taurigum.com

 

Attachment

 

  Tauriga Sciences

 

 

Tauriga Sciences